CMS recently announced some of the quality measures that are being truncated or suppressed for 2022 due to ICD-10 updates from October 1, 2022. 

2022 MIPS Quality Measures Impacted by ICD-10 Updates Effective October 1, 2022

ICD-10 code updates are effective annually on October 1, but quality measure specifications can’t be updated until the next MIPS program year. CMS has analyzed and assessed the quality measures to evaluate which measures are significantly impacted (greater than 10%) by the ICD-10 code updates. 

If a MIPS quality measure is impacted by 10% or more by ICD-10 code changes, such MIPS quality measure will be:
     • Truncated, the 2022 performance period and subsequent performance score for the affected quality measure will be based only on the first 9 months of the 12-month performance period 
     OR 
     • Suppressed for the 2022 performance period. 

The criteria used to make such determination is as follows:
     • Greater than 10% code changes in the measure numerator, denominator, exclusions, and exceptions.
     • Clinical guideline changes, new products, or procedures reflected in ICD-10 code changes.
     • Feedback on a measure received from measure developers and stewards.

Measures identified for Truncation – Medicare Part B Claims Measures
Quality ID# 134 – Preventive Care and Screening: Screening for Depression and Follow-Up Plan
Quality ID# 416 – Emergency Medicine: Emergency Department Utilization for CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years

Measures Identified for Truncation – MIPS Clinical Quality Measures (CQMs)
Quality ID# 6 – Coronary Artery Disease (CAD): Antiplatelet Therapy
Quality ID# 134 – Preventive Care and Screening: Screening for Depression and Follow-Up Plan
Quality ID# 282 – Dementia: Functional Status Assessment

Measures Identified for Suppression – Electronic Clinical Quality Measures (eCQMs)
CMS 135v10 – Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
CMS 130v10 – Colorectal Cancer Screening
CMS 2v11 – Preventive Care and Screening: Screening for Depression and Follow-Up Plan
CMS 165v10 – Controlling High Blood Pressure
CMS 155v10 – Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents
CMS 149v10 – Dementia: Cognitive Assessment
CMS 136v11 – Follow-Up Care for Children Prescribed ADHD Medication (ADD)

Notes: 
• Only quality measures supported by MEDENT are listed above. In the PDF below, the full list of measures affected is included.
• When the PDF was sent out by CMS 12/30/22, the eCQM measure versions were for 2023. CMS sent out a correction 1/4/23 indicating the measure versions should be for 2022.